The Onco Semantics R&D Lab on a mission to decode Cancer’s language and enable Humans to develop High-precision Drugs!
Drug resistance remains a formidable challenge in cancer treatment, with a range of implications such as variable drug efficacy across patient populations (due to insufficient target validation during drug discovery), unexpected side effects, inconsistent therapeutic outcomes, and increased economic burdens for pharmaceutical companies, hospitals, and patients.
OncoGalactica : To investigate the molecular causes of drug resistance in solid tumour conditions, Darwin (Bio + AI) has been actively developing OncoGalactica, its flagship AI Oncology Semantic framework, to:
1. Integrate multi-dimensional molecular and clinical oncology data with AI semantics.
2. Decipher causal relationships between genes and downstream receptor and signalling proteins.
3. Reconstruct the unique molecular aetiology of individual patients.
4. Identify key molecular mechanisms driving carcinogenesis and drug resistance in solid tumours with patient-level granularity.
Clinical Validation Trial : In a multi-centre clinical validation trial conducted to validate the accuracy of OncoGalactica in investigating the molecular causes of drug resistance in advanced HER2-positive breast cancer patients who had previously developed resistance to trastuzumab and taxanes, 11 patients in the treatment group, who were treated with an OncoGalactica-recommended combination of pertuzumab and alpelisib, showed an impressive Clinical Benefit Ratio (CBR) of 90.9% with 0.0% drug-related toxicities. This indicates the accuracy of OncoGalactica in investigating the molecular causes of drug resistance in solid tumour conditions with patient-level granularity.
Please check the “Research” page to get a high-level understanding of our OncoGalactica R&D, use cases, and key milestones.
Contact Us: For more information about Darwin (Bio + AI) and its research goals, please write to vamsi.ar@darwinbio.ai.
Privacy Disclaimer: At Darwin (Bio + AI), we prioritise user privacy and anonymity. Therefore, our digital assets do not utilise cookies or user behaviour tracking tools.